HemostOD

HemostOD is pioneering the ex vivo manufacturing of engineered, universal platelets to address critical unmet needs in transfusion medicine and targeted drug delivery. Its core technology involves creating an immortalized megakaryocyte cell line and using a microfluidic bioreactor to produce scalable, high-quality platelets. The company has secured seed funding and grants, established key partnerships, and is advancing multiple preclinical programs toward clinical development.

Proprietary, scalable platform for ex vivo manufacturing of engineered human platelets. It involves immortalizing hematopoietic progenitors, engineering them to be HLA-low and/or load therapeutic cargo, differentiating them into megakaryocytes, and using a microfluidic bioreactor to fragment megakaryocytes into functional platelets.

HemostOD competes in the nascent field of ex vivo platelet production with a few other biotechs and academic consortia globally. Its differentiation lies in its integrated, scalable platform and focus on HLA engineering. For targeted delivery, it faces competition from established modalities like lipid nanoparticles and viral vectors, but its CAR-PLT technology offers a novel, biologically-inspired alternative.